An observational study in Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center. Terminated at 1 site in United States. Open to female participants aged 25 Years to 76 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-28.
Sponsored by Dartmouth-Hitchcock Medical Center · Observational
The purpose of this study is to determine whether an experimental alternative imaging method, Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled respiratory system to examine the breasts for cancer. The NIR system uses light beams to produce an image or picture of the inside of the breast. The respiratory system will help researchers get more information about the breast tissue by changing the amount of oxygen the tissue receives during NIR imaging.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 8 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Dartmouth-Hitchcock Medical Center is the lead sponsor of 472 studies on the registry; 68 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 20 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Females with locally advanced breast cancer defined as being clinically appropriate for neoadjuvant therapy and healthy volunteers
NORMAL cohort
UNDER TREATMENT cohort
Exclusion Criteria:
both cohorts
Pre-existing respiratory conditions:
Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy
Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams
Quantify tumor oxygenation response in patients imaged.Determine capability of imaging dynamic to capture oxygenation changes within the tumor.
Analyze captured data from use of dynamic NIR topographic oximetry (in a cohort of women receiving conventional anthracycline/taxane based adjuvant chemotherapy).Quantify pathological and clinical outcomes.
Time frame: 18 weeks approximately
This study is terminated, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dartmouth-Hitchcock Medical Center